Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ANDA Approvals Break Record, May Set New Normal

Jul 11 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Jul 27 2015

ANDA Lull Begins: OGD Receives Four Applications In July

Aug 25 2014

ANDA Approvals Soar, But Does FDA Need To Do More?

May 16 2016

Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending

Jul 04 2017

ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals

May 10 2017

ANDA Approvals, Complete Responses Hit Record In FY 2016

Oct 12 2016

Generic Industry Gets 267 Reasons From FDA To Pursue ANDA Development

Jun 28 2017

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Jun 28 2017

Additional Topics

United States Generic Drugs Regulation Approvals FDA BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.